Increased gene copy number of ERG on chromosome 21 but not TMPRSS2-ERG fusion predicts outcome in prostatic adenocarcinomas

Antoun Toubaji, Roula Albadine, Alan Keith Meeker, William B Isaacs, Tamara Lotan, Michael C. Haffner, Alcides Chaux, Jonathan Ira Epstein, Misop Han, Patrick Walsh, Alan Wayne Partin, Angelo Michael Demarzo, Elizabeth A Platz, George J. Netto

Research output: Contribution to journalArticle

Abstract

The role of TMPRSS2-ERG gene fusion in prostate cancer prognostication remains controversial. We evaluated the prognostic role of TMPRSS2-ERG fusion using fluorescence in situ hybridization analysis in a case-control study nested in The Johns Hopkins retropubic radical prostatectomy cohort. In all, 10 tissue microarrays containing paired tumors and normal tissues obtained from 172 cases (recurrence) and 172 controls (non-recurrence) matched on pathological grade, stage, race/ethnicity, and age at the time of surgery were analyzed. All radical prostatectomies were performed at our institution between 1993 and 2004. Recurrence was defined as biochemical recurrence, development of clinical evidence of metastasis, or death from prostate carcinoma. Each tissue microarray spot was scored for the presence of TMPRSS2-ERG gene fusion and for ERG gene copy number gains. The odds ratio of recurrence and 95% confidence intervals were estimated from conditional logistic regression. Although the percentage of cases with fusion was slightly lower in cases than in controls (50 vs 57%), the difference was not statistically significant (P

Original languageEnglish (US)
Pages (from-to)1511-1520
Number of pages10
JournalModern Pathology
Volume24
Issue number11
DOIs
StatePublished - Nov 2011

Fingerprint

Chromosomes, Human, Pair 21
Gene Dosage
Adenocarcinoma
Recurrence
Gene Fusion
Prostatectomy
Fluorescence In Situ Hybridization
Case-Control Studies
Prostate
Prostatic Neoplasms
Logistic Models
Odds Ratio
Confidence Intervals
Neoplasm Metastasis
Carcinoma
Neoplasms

Keywords

  • fluorescence in situ hybridization
  • nested case-control study
  • prognosis
  • prostate adenocarcinoma
  • TMPRSS2-ERG fusion

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

@article{321d9b2244374e6aa94f4b67ce02c489,
title = "Increased gene copy number of ERG on chromosome 21 but not TMPRSS2-ERG fusion predicts outcome in prostatic adenocarcinomas",
abstract = "The role of TMPRSS2-ERG gene fusion in prostate cancer prognostication remains controversial. We evaluated the prognostic role of TMPRSS2-ERG fusion using fluorescence in situ hybridization analysis in a case-control study nested in The Johns Hopkins retropubic radical prostatectomy cohort. In all, 10 tissue microarrays containing paired tumors and normal tissues obtained from 172 cases (recurrence) and 172 controls (non-recurrence) matched on pathological grade, stage, race/ethnicity, and age at the time of surgery were analyzed. All radical prostatectomies were performed at our institution between 1993 and 2004. Recurrence was defined as biochemical recurrence, development of clinical evidence of metastasis, or death from prostate carcinoma. Each tissue microarray spot was scored for the presence of TMPRSS2-ERG gene fusion and for ERG gene copy number gains. The odds ratio of recurrence and 95{\%} confidence intervals were estimated from conditional logistic regression. Although the percentage of cases with fusion was slightly lower in cases than in controls (50 vs 57{\%}), the difference was not statistically significant (P",
keywords = "fluorescence in situ hybridization, nested case-control study, prognosis, prostate adenocarcinoma, TMPRSS2-ERG fusion",
author = "Antoun Toubaji and Roula Albadine and Meeker, {Alan Keith} and Isaacs, {William B} and Tamara Lotan and Haffner, {Michael C.} and Alcides Chaux and Epstein, {Jonathan Ira} and Misop Han and Patrick Walsh and Partin, {Alan Wayne} and Demarzo, {Angelo Michael} and Platz, {Elizabeth A} and Netto, {George J.}",
year = "2011",
month = "11",
doi = "10.1038/modpathol.2011.111",
language = "English (US)",
volume = "24",
pages = "1511--1520",
journal = "Modern Pathology",
issn = "0893-3952",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - Increased gene copy number of ERG on chromosome 21 but not TMPRSS2-ERG fusion predicts outcome in prostatic adenocarcinomas

AU - Toubaji, Antoun

AU - Albadine, Roula

AU - Meeker, Alan Keith

AU - Isaacs, William B

AU - Lotan, Tamara

AU - Haffner, Michael C.

AU - Chaux, Alcides

AU - Epstein, Jonathan Ira

AU - Han, Misop

AU - Walsh, Patrick

AU - Partin, Alan Wayne

AU - Demarzo, Angelo Michael

AU - Platz, Elizabeth A

AU - Netto, George J.

PY - 2011/11

Y1 - 2011/11

N2 - The role of TMPRSS2-ERG gene fusion in prostate cancer prognostication remains controversial. We evaluated the prognostic role of TMPRSS2-ERG fusion using fluorescence in situ hybridization analysis in a case-control study nested in The Johns Hopkins retropubic radical prostatectomy cohort. In all, 10 tissue microarrays containing paired tumors and normal tissues obtained from 172 cases (recurrence) and 172 controls (non-recurrence) matched on pathological grade, stage, race/ethnicity, and age at the time of surgery were analyzed. All radical prostatectomies were performed at our institution between 1993 and 2004. Recurrence was defined as biochemical recurrence, development of clinical evidence of metastasis, or death from prostate carcinoma. Each tissue microarray spot was scored for the presence of TMPRSS2-ERG gene fusion and for ERG gene copy number gains. The odds ratio of recurrence and 95% confidence intervals were estimated from conditional logistic regression. Although the percentage of cases with fusion was slightly lower in cases than in controls (50 vs 57%), the difference was not statistically significant (P

AB - The role of TMPRSS2-ERG gene fusion in prostate cancer prognostication remains controversial. We evaluated the prognostic role of TMPRSS2-ERG fusion using fluorescence in situ hybridization analysis in a case-control study nested in The Johns Hopkins retropubic radical prostatectomy cohort. In all, 10 tissue microarrays containing paired tumors and normal tissues obtained from 172 cases (recurrence) and 172 controls (non-recurrence) matched on pathological grade, stage, race/ethnicity, and age at the time of surgery were analyzed. All radical prostatectomies were performed at our institution between 1993 and 2004. Recurrence was defined as biochemical recurrence, development of clinical evidence of metastasis, or death from prostate carcinoma. Each tissue microarray spot was scored for the presence of TMPRSS2-ERG gene fusion and for ERG gene copy number gains. The odds ratio of recurrence and 95% confidence intervals were estimated from conditional logistic regression. Although the percentage of cases with fusion was slightly lower in cases than in controls (50 vs 57%), the difference was not statistically significant (P

KW - fluorescence in situ hybridization

KW - nested case-control study

KW - prognosis

KW - prostate adenocarcinoma

KW - TMPRSS2-ERG fusion

UR - http://www.scopus.com/inward/record.url?scp=80455174007&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80455174007&partnerID=8YFLogxK

U2 - 10.1038/modpathol.2011.111

DO - 10.1038/modpathol.2011.111

M3 - Article

VL - 24

SP - 1511

EP - 1520

JO - Modern Pathology

JF - Modern Pathology

SN - 0893-3952

IS - 11

ER -